ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Mitigating effect of naringenin on potassium bromate-induced nephrotoxicity in vivo.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The usage of potassium bromate (PB) in various consumer items and food and chemical industries poses a serious health risk like nephrotoxicity along with other toxic abuses. The compound elicits mild to severe toxic insults in a dose-dependent way in vivo and can even trigger carcinogenesis if exposed for long. This investigation ascertains the protective effect of naringenin (NIR), a polyphenol, in the PB-challenged rats. The animals were categorized into five treatment groups: Group I (control), and Groups II and III were treated with PB alone (100 mg/kg) and NIR alone (20 mg/kg), respectively. The groups- IV and V were administered with NIR at 20 and 40 mg/kg in the PB-exposed rats. The animals were killed to get their kidney and blood samples for biochemical, molecular, and histological alaysis. The group II exhibited an enhanced level of renal function and toxicity markers in serum, validating nephrotoxicity. Further, dysregulated redox parameters (GSH and MDA) and suppressed antioxidant enzymes (SOD and CAT) consolidated the same. Group III showed negligible toxicity, with most of the parameters' values close to the control. Intriguingly, groups- IV and V bestowed remarkable alleviation in the PB-induced nephrotoxicity in a dose -dependent way. In addition, the comet assay and histological evaluation further confirmed these findings. The study concludes that NIR effectively protects against PB-induced nephrotoxicity in rats attributed by regulating oxidative stress and promoting structural restoration at both macromolecular and cellular levels. Therefore, NIR is a suitable candidate for use in consumer products containing PB or as a treatment to alleviate nephrotoxicity caused by PB or similar compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.